Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8102978 | 0.80 | TSHR (0.61) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL8096462 | 0.79 | CYP2C19 (0.52) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL13119596 | 0.79 | CYP2C19 (0.52) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL8100779 | 0.78 | TSHR (0.52) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL13444996 | 0.76 | CYP2C19 (0.65) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL13621146 | 0.75 | ALDH1A1 (0.74) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL7419984 | 0.75 | ALDH1A1 (0.70) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL8100592 | 0.73 | SMN1; SMN2 (0.53) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL25658103 | 0.73 | KDM4E (0.60) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL8100774 | 0.73 | CYP2C19 (0.50) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | KLK7, KLK5, KLKB1 | ALDH1A1 4057/4885TSHR 2691/4885CYP2C9 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.